ArticleFrontiers in veterinary science2025
Serological and molecular surveillance of infectious bovine rhinotracheitis in Kazakhstan.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- First detection and molecular characterization of influenza D virus in livestock from Kazakhstan reveals circulation of the D/Yama2019 lineage.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Infectious bovine rhinotracheitis (IBR), caused by bovine herpesvirus type 1 (BoHV-1), remains endemic in Kazakhstan. Despite the absence of vaccination, comprehensive multi-year data on the virus circulation have been limited. Methods: A three-year surveillance between 2023 and 2025 was conducted in unvaccinated cattle from all 17 administrative regions a total of 8,590 serum samples and 4,795 nasal swabs. Serological monitoring was performed using two validated ELISA systems (IDEXX IBR gE Ab Test and ID Screen® IBR Indirect ELISA). Molecular detection employed real-time PCR on nasal swabs, and virus-isolation attempts were carried out on Vero cell monolayers. National reference serum panels were developed and externally validated at the Friedrich-Loeffler-Institut (Germany). Results: Serological testing revealed consistently high antibody prevalence-69.13% (2023), 80.64% (2024), and 82.79% (2025)-with marked regional variation. PCR positivity was 11.2% (280/2,500) in 2024 but only 0.43% (10/2,295) in 2025, indicating subclinical circulation and intermittent viral shedding. All virus-isolation attempts were negative, consistent with low viral loads and latent infection. The validated serum panels achieved > 95% concordance with international reference sera and were successfully implemented for national QA/QC. Conclusion: These findings confirm persistent BoHV-1 endemicity in Kazakhstan and highlight the diagnostic and epidemiological framework necessary for harmonized surveillance, DIVA-compatible vaccination (Differentiating Infected from Vaccinated Animals), and progressive alignment with WOAH eradication programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.